Oxford Global are proud to present the new Inhalation & Respiratory Drug Delivery Congress, 18 鈥� 19 May 2016, London, UK. Our unique event will address key improvements in the development and formulation of inhaled therapies as well as inhalation devices and analytics.
The inhalation and respiratory drug delivery market represents a smaller area of the global drug delivery industry that is growing at a substantial pace. Thanks to recent advancements in pulmonary and nasal technologies as well as inhalation devices and analytics the industry is flourishing more than ever.
The conference will attract senior-level representatives from leading pharmaceutical companies such as GlaxoSmithKline, Novartis and AstraZeneca. Key presentations will include dry powder updates by Frank Thielmann, Operational Lead, Inhalation New Solids from Novartis and analytical tools for inhaled medicines by Jan Olof Svensson, Principal Scientist Inhalation from AstraZeneca.
Our new conference features two highly interactive streams: day 1 will be devoted to the key developments and formulation of inhaled therapies and Day 2 will focus on key updates in inhalation devices and analytics. Our highly esteemed speakers will cover such important areas as regulatory considerations for inhaled therapies, future directions and inhalation and respiratory drug delivery research and novel technologies for pulmonary and nasal drug delivery.
Co-located with the 2nd Annual Formulation & Drug Delivery Congress, this two-day highly stimulating conference will bring together over 150 senior formulation, inhalation and drug delivery representatives and solution providers to engage in scientific discussions and network about the hottest areas of the industry. Attendees will also have the unique chance to participate in pre-organised 1-2-1 meetings.
To find out about the latest conference updates, do not miss to follow us on Twitter @FDDCongress and join the event conversation on #FDDC16. For more details on how to register for the meeting contact marketing@oxfordglobal.com.uk.
The inhalation and respiratory drug delivery market represents a smaller area of the global drug delivery industry that is growing at a substantial pace. Thanks to recent advancements in pulmonary and nasal technologies as well as inhalation devices and analytics the industry is flourishing more than ever.
The conference will attract senior-level representatives from leading pharmaceutical companies such as GlaxoSmithKline, Novartis and AstraZeneca. Key presentations will include dry powder updates by Frank Thielmann, Operational Lead, Inhalation New Solids from Novartis and analytical tools for inhaled medicines by Jan Olof Svensson, Principal Scientist Inhalation from AstraZeneca.
Our new conference features two highly interactive streams: day 1 will be devoted to the key developments and formulation of inhaled therapies and Day 2 will focus on key updates in inhalation devices and analytics. Our highly esteemed speakers will cover such important areas as regulatory considerations for inhaled therapies, future directions and inhalation and respiratory drug delivery research and novel technologies for pulmonary and nasal drug delivery.
Co-located with the 2nd Annual Formulation & Drug Delivery Congress, this two-day highly stimulating conference will bring together over 150 senior formulation, inhalation and drug delivery representatives and solution providers to engage in scientific discussions and network about the hottest areas of the industry. Attendees will also have the unique chance to participate in pre-organised 1-2-1 meetings.
To find out about the latest conference updates, do not miss to follow us on Twitter @FDDCongress and join the event conversation on #FDDC16. For more details on how to register for the meeting contact marketing@oxfordglobal.com.uk.
